296 related articles for article (PubMed ID: 12482341)
41. Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.
Cucuianu A; Stoia M; Farcaş A; Dima D; Zdrenghea M; Paţiu M; Olinic D; Petrov L
Rom J Intern Med; 2006; 44(4):397-406. PubMed ID: 18386616
[TBL] [Abstract][Full Text] [Related]
42. Structural, antigenetic and transcriptional characteristics in peripheral blood CD34+ progenitor cells from polycythemia vera patients: evidence for delayed determination.
Wickenhauser C; Pérez F; Siebolts U; Lorenzen J; Varus E; Frimpong S; Thiele J
Int J Oncol; 2003 Aug; 23(2):437-43. PubMed ID: 12851693
[TBL] [Abstract][Full Text] [Related]
43. Hemorheologic considerations in the pathogenesis of vascular occlusive events in polycythemia vera.
Pearson TC
Semin Thromb Hemost; 1997; 23(5):433-9. PubMed ID: 9387202
[TBL] [Abstract][Full Text] [Related]
44. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
45. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
46. [Fate of polycythemia vera treated by radioactive phosphorus. Apropos of a series of 303 patients followed for 12 to 24 years].
Tubiana M; Attie E; Parmentier C
Nouv Presse Med; 1975 Jun; 4(24):1781-6. PubMed ID: 1161478
[TBL] [Abstract][Full Text] [Related]
47. Laboratory investigations and prediction of thrombotic risk in polycythemia vera.
Boneu B
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):183-5. PubMed ID: 8036139
[TBL] [Abstract][Full Text] [Related]
48. A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP).
Finazzi G;
Pathol Biol (Paris); 2004 Jun; 52(5):285-8. PubMed ID: 15217715
[TBL] [Abstract][Full Text] [Related]
49. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
Tefferi A; Gangat N; Wolanskyj AP; Schwager S; Pardanani A; Lasho TL; Mesa R; McClure RF; Li CY; Hanson CA
Eur J Haematol; 2008 May; 80(5):386-90. PubMed ID: 18221390
[TBL] [Abstract][Full Text] [Related]
50. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
51. Inhibitory effect of the substance P and its derivative on erythropoietin-independent growth of erythroid progenitors in polycythemia vera.
Le Gall C; Ianotto JC; Hardy E; Ugo V; Eveillard JR; Ngo-Sack F; Bourquard P; Morice P; Berthou C
Leuk Res; 2008 May; 32(5):743-54. PubMed ID: 17980427
[TBL] [Abstract][Full Text] [Related]
52. [Polycythemia vera, clinical aspects and disease course].
Heilmann E; Köhler T
Fortschr Med; 1978 May; 96(18):941-6. PubMed ID: 648997
[TBL] [Abstract][Full Text] [Related]
53. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T
J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945
[TBL] [Abstract][Full Text] [Related]
54. Clinical features of polycythemia vera and essential thrombocythemia in Japan: retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group.
Dan K; Yamada T; Kimura Y; Usui N; Okamoto S; Sugihara T; Takai K; Masuda M; Mori M;
Int J Hematol; 2006 Jun; 83(5):443-9. PubMed ID: 16787877
[TBL] [Abstract][Full Text] [Related]
55. [Familial Vaquez's diseases].
Tursz T; Hakim J; Boivin P; Mallarmé J
Presse Med (1893); 1971 Dec; 79(53):2427-32. PubMed ID: 5156526
[No Abstract] [Full Text] [Related]
56. Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors.
Teng G; Zhou Y; Zhang Y; Hu N; Liu T; Han Y; Gao C; Zhang L; Bai J
Thromb Res; 2022 Apr; 212():38-43. PubMed ID: 35219930
[TBL] [Abstract][Full Text] [Related]
57. Red cell mass, spleen size and plasma erythropoietin in polycythaemia vera and apparent polycythaemia.
Johansson P; Safai-Kutti S; Lindstedt G; Suurküla M; Kutti J
Acta Haematol; 2002; 108(1):1-7. PubMed ID: 12145459
[TBL] [Abstract][Full Text] [Related]
58. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
59. Serum erythropoietin in the diagnosis of polycythemia vera. A follow-up study.
Remacha AF; Montserrat I; Santamaria A; Oliver A; Barceló MJ; Parellada M
Haematologica; 1997; 82(4):406-10. PubMed ID: 9299851
[TBL] [Abstract][Full Text] [Related]
60. Hyperviscosity in polycythemia vera and other red cell abnormalities.
Kwaan HC; Wang J
Semin Thromb Hemost; 2003 Oct; 29(5):451-8. PubMed ID: 14631544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
